Shareholders to Vote on Share Issuance Authority and Takeover Code Waiver

summarizeSummary

CytoMed Therapeutics announced its Annual General Meeting, where shareholders will vote on key proposals including authorizing directors to issue new shares for future offerings and waiving the Singapore Takeover Code to enhance M&A flexibility.

check_boxKey Events

• Share Issuance Authorization

  Shareholders will vote on granting directors authority to issue new ordinary shares for follow-on offerings and other purposes, effective until the next Annual General Meeting. This provides crucial flexibility for future capital raises.

• Takeover Code Waiver Proposal

  A proposal to waive the application of the Singapore Code on Take-overs and Mergers aims to increase flexibility for fundraising and M&A transactions by relying on U.S. SEC and Nasdaq rules.

• Director Re-elections

  Two directors, Dr. YEW Chak Hua and Dr. TOH Keng Kiat, are up for re-election by rotation.

• Directors' Fees Approval

  Approval is sought for US$70,000 in directors' fees for the financial year ending December 31, 2026.

auto_awesomeAnalysis

CytoMed Therapeutics is seeking shareholder approval for critical measures that will provide significant flexibility for future capital raising and strategic transactions. Authorizing the board to issue new shares is essential for a micro-cap company like CytoMed Therapeutics to fund its operations and growth initiatives, though it introduces potential dilution. The proposed waiver of the Singapore Takeover Code is a strategic move to streamline future M&A and fundraising activities by aligning with U.S. disclosure rules, potentially making the company more attractive to larger investors. These approvals are vital for the company's long-term financial and strategic agility.